ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC) announced management will participate in three investor conferences in November 2026, with fireside chats and one-on-one meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC) announced management will participate in three investor conferences in November 2026, with fireside chats and one-on-one meetings.
Chats are scheduled for Guggenheim on November 10 at 10:30 a.m. ET, Stifel on November 11 at 2:00 p.m. ET, and Jefferies London on November 18 at 12:30 p.m. GMT. Webcasts will be available on the investor website, with replays available for 90 days following each event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:
- Guggenheim’s 3rd Annual Healthcare Innovation Conference – Participating in a fireside chat on Tuesday, November 10, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings.
- Stifel 2026 Healthcare Conference – Participating in a fireside chat on Wednesday, November 11, 2026, at 2:00 p.m. ET. Management will also be participating in one-on-one meetings.
- Jefferies London Healthcare Conference – Participating in a fireside chat on Wednesday, November 18, 2026, at 12:30 p.m. GMT. Management will also be participating in one-on-one meetings.
Webcasts of the fireside chat discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
